HomeCompareVMTHF vs PFE

VMTHF vs PFE: Dividend Comparison 2026

VMTHF yields 474.05% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMTHF wins by $40760.06M in total portfolio value
10 years
VMTHF
VMTHF
● Live price
474.05%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40760.11M
Annual income
$28,806,329,273.60
Full VMTHF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — VMTHF vs PFE

📍 VMTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMTHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMTHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMTHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMTHF
Annual income on $10K today (after 15% tax)
$40,293.91/yr
After 10yr DRIP, annual income (after tax)
$24,485,379,882.56/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, VMTHF beats the other by $24,485,356,753.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMTHF + PFE for your $10,000?

VMTHF: 50%PFE: 50%
100% PFE50/50100% VMTHF
Portfolio after 10yr
$20380.08M
Annual income
$14,403,178,242.07/yr
Blended yield
70.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VMTHF
No analyst data
Altman Z
-0.0
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMTHF buys
0
PFE buys
0
No recent congressional trades found for VMTHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMTHFPFE
Forward yield474.05%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$40760.11M$51.1K
Annual income after 10y$28,806,329,273.60$27,210.54
Total dividends collected$39707.63M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMTHF vs PFE ($10,000, DRIP)

YearVMTHF PortfolioVMTHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$58,105$47,404.60$9,161$701.38+$48.9KVMTHF
2$319,595$257,422.91$8,610$859.79+$311.0KVMTHF
3$1,665,249$1,323,282.78$8,366$1,081.25+$1.66MVMTHF
4$8,225,711$6,443,893.93$8,483$1,405.66+$8.22MVMTHF
5$38,549,580$29,748,069.43$9,084$1,907.24+$38.54MVMTHF
6$171,541,094$130,293,043.94$10,418$2,732.78+$171.53MVMTHF
7$725,407,583$541,858,612.30$13,007$4,193.56+$725.39MVMTHF
8$2,917,676,445$2,141,490,330.46$18,010$7,005.87+$2917.66MVMTHF
9$11,171,756,198$8,049,842,402.84$28,216$12,979.89+$11171.73MVMTHF
10$40,760,108,406$28,806,329,273.60$51,081$27,210.54+$40760.06MVMTHF

VMTHF vs PFE: Complete Analysis 2026

VMTHFStock

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Full VMTHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VMTHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMTHF vs SCHDVMTHF vs JEPIVMTHF vs OVMTHF vs KOVMTHF vs MAINVMTHF vs JNJVMTHF vs MRKVMTHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.